Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 01-10 15:00:00

23.62

-0.36

-1.50%

High24.17	Low23.61	Vol8.45M
Open24.08	D1 Closing23.98	Amplitude2.34%
Mkt Cap63.09B	Tradable Cap50.03B	Total Shares2.67B
T/O201.00M	T/O Rate0.40%	Tradable Shares2.12B
P/B1.33	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":23.62,"timestamp":1736492400000,"preClose":23.98,"halted":0,"volume":8452381,"delay":0,"changeRate":-0.015,"floatShares":2118000000,"shares":2671000000,"eps":0.7914,"marketStatus":"Closed","change":-0.36,"latestTime":"01-10 15:00:00","open":24.08,"high":24.17,"low":23.61,"amount":201000000,"amplitude":0.0234,"askPrice":23.62,"askSize":180,"bidPrice":23.61,"bidSize":108,"shortable":0,"etf":0,"ttmEps":0.7914,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736731800000},"marketStatusCode":5,"adr":0,"adjPreClose":23.98,"symbolType":"stock","openAndCloseTimeList":[[1736472600000,1736479800000],[1736485200000,1736492400000]],"highLimit":26.38,"lowLimit":21.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2671326465,"isCdr":false,"pbRate":1.33,"roa":"--","peRate":29.845843,"roe":"4.32%","epsLYR":0.89,"committee":0.406921,"marketValue":63097000000,"turnoverRate":0.004,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2025-01-13.","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":13.16,"timestamp":1736496483014,"preClose":13.42,"halted":0,"volume":2367075,"delay":0,"premium":"-47.34"},"floatMarketCap":50039000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2502015215","title":"Fosun Pharmaceutical's Unit Gets China Nod for Registration of Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2502015215","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502015215?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:15","pubTimestamp":1736424934,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  drug registration application for the Fovinaciclib citrate capsules by unit Jinzhou Avanc Pharmaceutical, has been accepted by China's National Medical Products Administration, a Thursday bourse filing said.The indication under the application is locally advanced or metastatic breast cancer, where the drug should be used in combination with an aromatase inhibitor as initial endocrine therapy for premenopausal, postmenopausal, and perimenopausal female patients with breast cancer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK0183","BK0187","BK0196","BK0096","BK1230","BK1593","00656","BK0060","BK0188","BK1515","600196","BK0175","BK0028","02196","BK0012","BK0239"],"gpt_icon":0},{"id":"2502094731","title":"BRIEF-Shanghai Fosun Pharma Updates On Fovinaciclib Citrate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2502094731","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502094731?lang=en_us&edition=fundamental","pubTime":"2025-01-09 18:35","pubTimestamp":1736418946,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Updates On Fovinaciclib Citrate Capsules Jan 9  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG REGISTRATION APPLICATION FOR FOVINACICLIB CITRATE CAPSULES OF JINZHOU AVANC PHARMACEUTICAL ACCEPTED BY NMPAFurther company coverage: 600196.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O5094:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0012","BK0028","600196","BK0196","BK0188","BK0175","BK0187","BK0060","BK0183","BK0239"],"gpt_icon":0},{"id":"2502099036","title":"Shanghai Fosun Pharma -  Drug Registration Application for Fovinaciclib Citrate Capsules of Jinzhou Avanc Pharmaceutical Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2502099036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502099036?lang=en_us&edition=fundamental","pubTime":"2025-01-09 18:02","pubTimestamp":1736416945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O5094:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0175","BK0183","BK0028","BK0239","BK0187","600196","BK0188","BK0060","BK0196","BK0012"],"gpt_icon":0},{"id":"2500164089","title":"Shanghai Fosun Pharmaceutical (Group) Subsidiary's Cancer Drug's NDA Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2500164089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500164089?lang=en_us&edition=fundamental","pubTime":"2025-01-03 17:07","pubTimestamp":1735895277,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   said its subsidiary Jisimei  Pharmaceutical's Raltitrexed for Injection application for a new drug was accepted by the National Medical Products Administration , according to a Thursday filing with the bourse.Raltitrexed for Injection works as a monotherapy for the treatment of advanced colorectal cancer in patients who are not candidates for 5-FU/Leucovorin combination chemotherapy, the filing noted.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0060","BK0188","BK0187","BK1593","02196","BK0096","BK0183","BK0196","BK1515","BK0028","00656","BK0175","BK1191","BK0012","BK0239"],"gpt_icon":0},{"id":"2500946418","title":"Shanghai Fosun Pharma Says Drug Registration Applications Of Raltitrexed Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2500946418","media":"T-Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500946418?lang=en_us&edition=fundamental","pubTime":"2025-01-02 18:22","pubTimestamp":1735813327,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Shanghai Fosun Pharma -  Drug Registration Applications Of Raltitrexed For Injection Of Jisimei (Wuhan) Pharmaceutical Accepted By Nmpa.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0175","BK0183","BK0028","BK0239","BK0187","600196","BK0188","BK0060","BK0196","BK0012"],"gpt_icon":0},{"id":"2500179459","title":"Shanghai Fosun Pharma -  Drug Registration Applications of Raltitrexed for Injection of Jisimei (Wuhan) Pharmaceutical Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2500179459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500179459?lang=en_us&edition=fundamental","pubTime":"2025-01-02 17:06","pubTimestamp":1735808819,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250102:nFWN3NW0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0096","BK0028","600196","BK0183","BK0239","BK0060","BK0188","BK0187","BK0175","BK0012"],"gpt_icon":0},{"id":"2492954054","title":"Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954054","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954054?lang=en_us&edition=fundamental","pubTime":"2024-12-20 16:28","pubTimestamp":1734683284,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Group  subsidiary Henlius  signed a cooperation and license agreement with Palleon.The two parties will cooperate on developing Palleon's E-602 product and related combination therapy solutions in the field and commercialization in their respective licensed regions, according to a Thursday filing with the Shanghai bourse.Henlin shall pay Palleon royalties ranging between 8% and 12%, based on the annual net sales of the licensed products in the Henlin licensed territory.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","02696","BK0183","BK0239","BK1230","BK0187","BK0060","BK0175","BK0012","00656","600196","BK1161","BK0096","BK0028","BK0188"],"gpt_icon":0},{"id":"2492520147","title":"Fosun Pharmaceutical  Says Subsidiary Henlius Signs Collaboration and Licensing Agreement With Palleon","url":"https://stock-news.laohu8.com/highlight/detail?id=2492520147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492520147?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:17","pubTimestamp":1734603463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0175","BK0183","BK0028","BK0239","02696","BK0187","600196","BK0188","BK0060","BK0196","BK0012","BK1161"],"gpt_icon":0},{"id":"2492147427","title":"BRIEF-Fosun Pharmaceutical's Subsidiary Signs Agreement With Palleon","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147427","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492147427?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:17","pubTimestamp":1734603463,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun Pharmaceutical's Subsidiary Signs Agreement With PalleonDec 19  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS SUBSIDIARY SHANGHAI HENLIUS BIOTECH INC SIGNS COLLABORATION AND LICENSING AGREEMENT WITH PALLEON PHARMACEUTICALS INCSource textFurther company coverage: 600196.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK1161","BK0028","BK0196","600196","BK0012","BK0239","BK0187","02696","BK0096","BK0175","BK0060","BK0183"],"gpt_icon":0},{"id":"2492490424","title":"Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2492490424","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492490424?lang=en_us&edition=fundamental","pubTime":"2024-12-18 19:47","pubTimestamp":1734522466,"startTime":"0","endTime":"0","summary":"Regent Pacific Group's (HKG:0575) commercial strategic partner, Jiangsu Wanbang Biopharmaceutical Group, has submitted a new drug application (NDA) for Senstend to China's National Medical Products Ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","HKD","BK4585","BK4023","BK4588","BK1191","BK0239","BK0187","BK0060","BK0175","BK0196","BK1593","00575","BK0183","BK1515","BK0188","BK0012","BK0096","02196","BK0028","BK4526"],"gpt_icon":0},{"id":"2491406263","title":"Fosun Pharmaceutical Buys Back Nearly 3 Million Yuan Worth of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2491406263","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491406263?lang=en_us&edition=fundamental","pubTime":"2024-12-13 18:30","pubTimestamp":1734085856,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  bought back 185,500 ordinary H shares in the secondary market on Friday for nearly 2.7 million yuan, a same-day bourse filing said.The pharmaceutical company repurchased the shares between 14.30 yuan and 14.46 yuan each.The repurchased shares will be held as treasury shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK0060","BK0012","BK0187","00656","BK1593","BK0175","BK0239","BK0196","BK0096","02196","600196","BK0028","BK0183","BK0188","BK1191"],"gpt_icon":0},{"id":"2490483859","title":"Shanghai Fosun Pharma -  Ningbo Fuying Will Acquire Equity Interests of Suzhou Angel Fund in Amount of RMB44.00 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2490483859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490483859?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:51","pubTimestamp":1733921496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nFWN3NC0NJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0188","BK0239","BK0096","BK0187","BK0196","BK0028","600196","BK0183","BK0012","BK0175"],"gpt_icon":0},{"id":"2489109771","title":"Shanghai Fosun Pharmaceutical Gets Approval to Launch Tumor Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2489109771","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489109771?lang=en_us&edition=fundamental","pubTime":"2024-12-05 12:46","pubTimestamp":1733373970,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  secured approval from China's drug administrator to conduct phase Ib/II clinical trials of HLX43 for injection.The drug will be used to treat advanced or metastatic solid tumors, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK0188","BK0239","BK0096","BK0187","BK0196","BK0028","00656","600196","BK0183","BK0012","BK0175"],"gpt_icon":0},{"id":"2489098291","title":"Shanghai Fosun Pharmaceutical Gets Drug Registration for Pertuzumab Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2489098291","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489098291?lang=en_us&edition=fundamental","pubTime":"2024-12-05 12:32","pubTimestamp":1733373141,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196) obtained a drug registration for monoclonal antibody injection HLX11 from China's drug administrator.HLX11 is a pertuzumab biosimilar intended to be used in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0239","BK0012","BK0096","BK0196","BK0183","BK0188","BK0175","00656","BK0060","BK0028","600196"],"gpt_icon":0},{"id":"2488718442","title":"Shanghai Fosun Pharmaceutical Obtains Authorization for New Indication of Hans-Zhong Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488718442","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488718442?lang=en_us&edition=fundamental","pubTime":"2024-12-04 11:34","pubTimestamp":1733283273,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with pemetrexed and carboplatin.The new indication is for the \"first-line treatment of epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer,\" according to a Tuesday filing with the Shanghai bourse.The approval will further enhance the market competitiveness of the drug and bring more treatment options to patients with non-squamous non-small cell lung cancer in China, the company said.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0060","BK0188","BK0187","BK1593","02196","BK0096","BK0183","BK0196","BK1515","BK0028","00656","BK0175","BK1191","BK0012","BK0239"],"gpt_icon":0},{"id":"2488990787","title":"Shanghai Fosun Pharmaceutical (Group)'s Blood Health Medication Gets NMPA's Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2488990787","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488990787?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:08","pubTimestamp":1733224128,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   unit Hebei Wanbang Folon Pharmaceutical's Tao Hong Si Wu Granules drug registration application was accepted by China's National Medical Products Administration , according to a Tuesday filing with the Hong Kong bourse.The New Drug is a traditional Chinese medicine for nourishing blood, activating blood circulation, and removing blood stasis. It is intended to be used for blood deficiency and blood stasis syndrome, among other issues, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1230","BK0187","BK0096","00656","BK1515","02196","BK0175","BK0028","BK0183","BK0196","BK0012","BK0188","BK0239","BK1191","BK1593","600196","BK0060"],"gpt_icon":0},{"id":"2486239296","title":"Shanghai Fosun Pharmaceutical (Group) Unit's Cervical Dystonia Gets NMPA Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2486239296","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486239296?lang=en_us&edition=fundamental","pubTime":"2024-11-28 19:19","pubTimestamp":1732792783,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical   said China's National Medical Products Administration  approved Botulinum Toxin Type A for Injection new drug application, according to a Wednesday filing with the Hong Kong bourse.The drug, which is used for treating cervical dystonia in adults, was licensed to the company's unit, Fosun Pharmaceutical Industrial.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0187","BK1191","BK1593","BK0239","02196","600196","BK0012","BK0175","00656","BK1230","BK0060","BK0028","BK0188","BK1515","BK0183","BK0096"],"gpt_icon":0},{"id":"2486332124","title":"Fosun Pharma Gets Marketing Authorization for Botox Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2486332124","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486332124?lang=en_us&edition=fundamental","pubTime":"2024-11-28 10:55","pubTimestamp":1732762505,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained marketing authorization for botulinum toxin type A injection from China's state drug administrator.The injection is intended for treating cervical dystonia, according to a Wednesday filing with the Shanghai bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00656","BK0187","BK0096","BK0188","02196","600196","BK1515","BK0012","BK0196","BK0060","BK0183","BK0175","BK1191","BK0239","BK1593","BK0028"],"gpt_icon":0},{"id":"2486784128","title":"BRIEF-Shanghai Fosun Pharma Says NDA Of Botulinum Toxin Type A For Injection Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2486784128","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486784128?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:47","pubTimestamp":1732704478,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says NDA Of Botulinum Toxin Type A For Injection Approved By NMPANov 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:NDA OF BOTULINUM TOXIN TYPE A FOR INJECTION APPROVED BY NMPAFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY0MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0196","BK0239","BK0183","BK0028","BK0175","BK0187","BK0188","BK0012","BK0060","600196"],"gpt_icon":0},{"id":"2486846374","title":"Shanghai Fosun Pharma -  Nda of Botulinum Toxin Type a for Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2486846374","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486846374?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:04","pubTimestamp":1732701880,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY0MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0096","BK0028","600196","BK0183","BK0239","BK0060","BK0188","BK0187","BK0175","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.1167},{"period":"3month","weight":-0.0816},{"period":"6month","weight":0.0577},{"period":"1year","weight":-0.0215},{"period":"ytd","weight":-0.0495}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267132万元","compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.0153},{"period":"6month","weight":0.0664},{"period":"1year","weight":0.0976},{"period":"ytd","weight":-0.0547}],"survey":"　　上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单，本集团位列第7。由米内研究院主办的“中国医药工业百强系列榜单”，本集团成功入选“2022年度中国化药企业TOP100排行榜”，位列中国化药企业百强榜第6位；根据IQVIA统计，2023年第一季度本集团的医院用处方药销售收入位列全国第12位；根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书，本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1736528868659,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction